Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Up 3.9% - Here's Why

Key Points

• Shares rose 3.9% to $25.53 on Tuesday, but trading was thin at 39,443 shares—about an 83% decline from the average session volume.
• Several firms recently initiated or raised coverage (UBS buy, Guggenheim buy, Evercore outperform), leaving a MarketBeat consensus of "Moderate Buy" with a consensus price target of $44.25.
• Damora is a clinical-stage biotech developing galectin‑3 inhibitors (lead programs GB0139 and GB1211) and has a market cap of about $1.49 billion.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) shot up 3.9% on Tuesday . The stock traded as high as $25.53 and last traded at $25.53. 39,443 shares were traded during mid-day trading, a decline of 83% from the average session volume of 232,475 shares. The stock had previously closed at $24.57.

Analyst Upgrades and Downgrades

Several research firms have weighed in on DMRA. UBS Group began coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a "buy" rating and a $45.00 price objective for the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, December 29th. Zacks Research upgraded Damora Therapeutics, Inc. Common Stock to a "hold" rating in a report on Friday, January 9th. Guggenheim reiterated a "buy" rating and issued a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Finally, Evercore began coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an "outperform" rating and a $46.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Damora Therapeutics, Inc. Common Stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.25.

Damora Therapeutics, Inc. Common Stock Trading Up 0.5%

The firm has a fifty day simple moving average of $26.79 and a two-hundred day simple moving average of $20.82. The firm has a market cap of $1.49 billion, a PE ratio of -2.04 and a beta of 1.59.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $40,000. Geode Capital Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $266,000. Virtu Financial LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at approximately $49,000. Sigma Planning Corp purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $334,000. Finally, Two Sigma Investments LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at approximately $76,000. Hedge funds and other institutional investors own 14.20% of the company's stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.